|
RNF160 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.03490043996169E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.56509999965837E-07 |
| Normal-vs-Stage2 |
3.86419999998111E-07 |
| Normal-vs-Stage3 |
7.17710002540173E-10 |
| Normal-vs-Stage4 |
1.79600000427271E-08 |
| Stage1-vs-Stage2 |
1.859350E-01 |
| Stage1-vs-Stage3 |
2.827500E-02 |
| Stage1-vs-Stage4 |
6.562400E-02 |
| Stage2-vs-Stage3 |
7.727200E-01 |
| Stage2-vs-Stage4 |
6.748400E-01 |
| Stage3-vs-Stage4 |
8.667200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.02499997378658E-09 |
| Normal-vs-AfricanAmerican |
2.340700E-03 |
| Normal-vs-Asian |
1.55426999999264E-05 |
| Caucasian-vs-AfricanAmerican |
4.882000E-01 |
| Caucasian-vs-Asian |
9.563800E-01 |
| AfricanAmerican-vs-Asian |
5.702800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.98440178020587E-11 |
| Normal-vs-Female |
2.83169999670818E-08 |
| Male-vs-Female |
8.959700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.5032599999909E-05 |
| Normal-vs-Age(41-60Yrs) |
7.84070031123463E-10 |
| Normal-vs-Age(61-80Yrs) |
1.06469999483494E-08 |
| Normal-vs-Age(81-100Yrs) |
2.717700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.294300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.072400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.128000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.528400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.703200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.425400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.318300E-02 |
| Classical-VS-Follicular |
4.682800E-01 |
| Classical-VS-Other |
2.338800E-01 |
| Classical-VS-Normal |
4.04540000387144E-08 |
| Tall-VS-Follicular |
1.544980E-01 |
| Tall-VS-Other |
8.643200E-01 |
| Tall-VS-Normal |
2.65189999959503E-07 |
| Follicular-VS-Other |
4.454400E-01 |
| Follicular-VS-Normal |
3.50999999998436E-06 |
| Other-VS-Normal |
2.617200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.71630004547541E-09 |
| Normal-vs-N1 |
7.66079999992009E-07 |
| N0-vs-N1 |
8.816000E-01 |
|
|
